Search clinical trials for: 8H9

Total 179 results

Y-mAbs Therapeutics

Terminated

Intraperitoneal RIT With 131I-8H9 for Pts With DSRCT and Other Solid Tumors Involving the Peritoneum

Peritoneal Cancer

United States
Memorial Sloan Kettering Cancer Center

Terminated

Tumor Detection Using Iodine-131-Labeled Monoclonal Antibody 8H9

Sarcoma | Neuroblastoma | CNS Cancer

United States
Y-mAbs Therapeutics

Terminated

131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases

Neuroblastoma | Leptomeningeal Metastases | CNS Metastases

United States, Denmark, Japan, Spain
Calithera Biosciences, Inc

Completed

A Comparative, Pharmacokinetic Study of CB-839 Capsule and Tablet Formulations in Healthy Adults

Healthy Volunteers

United States
BTL Industries Ltd.

Completed

Effect of the BTL-899 Therapy for Non-invasive Lipolysis and Circumference Reduction of Abdomen

Improvement of Abdomen Appearance

Bulgaria
Auspex Pharmaceuticals, Inc.

Completed

A Pilot Study Of SD-809 (Deutetrabenazine) In Moderate To Severe Tourette Syndrome (TS)

TOURETTE SYNDROME

United States
BTL Industries Ltd.

Completed

Effect of BTL-899 Device for Non-invasive Lipolysis on Human Upper Arms

Fat Burn

Bulgaria
AbbVie

Completed

A Phase 1 Study of ABT-869 in Subjects With Solid Tumors

Solid Tumor
AbbVie (prior sponsor, Abbott)
Genentech, Inc.

Completed

Pharmacokinetic Study To Evaluate Effect of Food and Diurnal Variation on ABT-869

Advanced Solid Tumors
AbbVie (prior sponsor, Abbott)
Genentech, Inc.

Completed

Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer (NSCLC)

United States, Canada, France, Singapore, Taiwan
BTL Industries Ltd.

Completed

Non-invasive Lipolysis and Improvement of Muscle Tone in Lateral Abdomen

Fat Burn

United States
BTL Industries Ltd.

Completed

Histological Evaluation of BTL-899 Device´s Effect on Fat Tissue

Fat Burn

United States
BTL Industries Ltd.

Completed

rPMS and Radiofrequency for Abdominal Toning and Reduction of Subcutaneous Fat

Fat Burn

United States
BTL Industries Ltd.

Completed

Non-invasive Lipolysis on Human Thighs and Saddlebags

Adipose Tissue Reduction

Bulgaria
BTL Industries Ltd.

Completed

High-Intensity Focused Electromagnetic Procedure and Radiofrequency for Toning of Buttocks

Muscle Tone

United States
Janssen Research & Development, LLC

Withdrawn

A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer

Prostatic Neoplasms, Castration-Resistant

United States
BTL Industries Ltd.

Completed

Non-invasive Lipolysis and Improvement of Muscle Tone in Upper Arms

Fat Disorder

United States
BTL Industries Ltd.

Completed

Fat Reduction and Muscle Toning of Thighs

Fat Burn

United States
BTL Industries Ltd.

Completed

Non-invasive Lipolysis and Improvement of Muscle Tone in Inner Thighs

Fat Disorder

United States
BTL Industries Ltd.

Completed

Clinical Evaluation of the BTL-899 Device for Non-invasive Lipolysis on Human Fat Tissue

Improvement of Abdomen Appearance

Bulgaria
AbbVie (prior sponsor, Abbott)
Genentech, Inc.

Completed

Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)

Advanced Hepatocellular Carcinoma

United States, Canada, Singapore, Taiwan
FAScinate Therapeutics Inc.
Parexel

Recruiting

A Study to Evaluate Safety and Efficacy of KM-819 in Healthy Adults and Participants With Parkinson's Disease

Parkinson Disease

United States
Kainos Medicine Inc.

Completed

Phase I, KM-819 in Healthy Subjects for Parkinson's Disease

Parkinson's Disease

Korea, Republic of
Anchiano Therapeutics Israel Ltd.

Completed

Phase 1/2a Study of DTA-H19 in Advanced Stage Ovarian Cancer

Ovarian Cancer

Israel
Anchiano Therapeutics Israel Ltd.

Completed

Phase 1/2a DTA-H19 in Patients With Unresectable Pancreatic Cancer

Pancreatic Neoplasms

United States, Israel
Kainos Medicine Inc.
Parexel

Recruiting

Trial to Evaluate the Efficacy and Safety of KM-819 Treatment to Slow the Progression of Multiple System Atrophy (MSA)

Multiple System Atrophy

Korea, Republic of
BTL Industries Ltd.

Unknown

Effect of the BTL-899 Therapy for Non-invasive Lipolysis and Circumference Reduction of Abdomen When Compared to a Sham Treatment

Improvement of Abdomen Appearance

Bulgaria
AbbVie

Completed

An Extension Study of Linifanib (ABT-869) in Subjects With Advanced or Metastatic Solid Tumors

Advanced Solid Tumors
Vertex Pharmaceuticals Incorporated

Completed

Study of VX-809 in Cystic Fibrosis Subjects With the ∆F508-CFTR Gene Mutation

Cystic Fibrosis

United States, Belgium, Canada, Netherlands, Germany
Abbott

Terminated

A Study Evaluating the Bioavailability of Two Formulations of Linifanib and Food Effect on Pharmacokinetics of Linifanib in Subjects With Advanced or Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors

United States
Abbott

Completed

To Compare Relative Bioavailability of Two Clinical Formulations of Linifanib.

Advanced Solid Tumors

United States
Auspex Pharmaceuticals, Inc.

Completed

Addressing Involuntary Movements in Tardive Dyskinesia (AIM-TD)

Tardive Dyskinesia

United States, Czechia, Germany, Hungary, Poland, Slovakia
BTL Industries Ltd.

Completed

Combination Treatment With BTL-899 and HPM-6000UF Devices II

Muscle Weakness

United States
Vanderbilt-Ingram Cancer Center

Terminated

Linifanib in Treating Patients With Advanced, Refractory Colorectal Cancer

Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer | Stage IVB Colon Cancer | Stage IVB Rectal Cancer

United States
Prokarium Ltd

Recruiting

A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer (PARADIGM-1)

NMIBC | Non Muscle Invasive Bladder Cancer | High Risk NMIBC

United States
BTL Industries Ltd.

Active, not recruiting

Combination Treatment With BTL-899 and HPM-6000UF Devices

Pelvic Floor Disorders

United States
Auspex Pharmaceuticals, Inc.

Completed

Reducing Involuntary Movements in Participants With Tardive Dyskinesia (RIM-TD)

Tardive Dyskinesia

United States, Czechia, Germany, Hungary, Poland, Slovakia
Teva Branded Pharmaceutical Products R&D, Inc.
Nuvelution TS Pharma, Inc.

Terminated

Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents (ARTISTS)

Tourette Syndrome

United States, Argentina, Australia, Canada, Colombia, Denmark, Hungary, Italy, Korea, Republic of, Mexico, Poland, Russian Federation, Serbia, Spain, Ukraine
National Cancer Institute (NCI)

Recruiting

Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Leptomeningeal Neoplasm | Recurrent Lung Non-Small Cell Carcinoma

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Terminated

A Study to Test if TEV-50717 is Safe and Effective in Relieving Abnormal Involuntary Movements in Cerebral Palsy

Cerebral Palsy, Dyskinetic

United States, Italy, Russian Federation, Spain, Denmark, Israel, Poland, Ukraine, United Kingdom
Abbott

Terminated

A Pharmacokinetic Study to Access How the Body Absorbs and Removes Linifanib in Male Patients With Advanced Solid Tumors.

Advanced Solid Tumors

United States
Calithera Biosciences, Inc

Completed

Study of the Glutaminase Inhibitor CB-839 in Solid Tumors

Renal Cell Carcinoma | Non Small Cell Lung Cancer | Mesothelioma | Solid Tumors | Triple-Negative Breast Cancer | Fumarate Hydratase (FH)-Deficient Tumors | Succinate Dehydrogenase (SDH)-Deficient Gastrointestinal Stromal Tumors (GIST) | Succinate Dehydrogenase (SDH)-Deficient Non-gastrointestinal... and other conditions

United States
Auspex Pharmaceuticals, Inc.

Completed

Aim to Reduce Movements in Tardive Dyskinesia (ARM-TD)

Tardive Dyskinesia

United States, Poland, Czechia, Slovakia
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Study of TEV-50717 (Deutetrabenazine) for the Treatment of Dyskinesia in Cerebral Palsy in Children and Adolescents (RECLAIM-DCP)

Cerebral Palsy, Dyskinetic

United States, Denmark, Israel, Italy, Poland, Russian Federation, Spain, Ukraine, United Kingdom, Canada, Slovakia, Belgium
University Hospital, Bonn

Completed

Auditory Beat Stimulation and Behavioural Variant of Frontotemporal Dementia

Anxiety | bvFTD

Germany
Anchiano Therapeutics Israel Ltd.

Terminated

Codex: Study of Inodiftagene Vixteplasmid (BC-819) in Unresponsive NMIBC

Non-muscle Invasive Bladder Cancer (NMIBC)

United States
AbbVie (prior sponsor, Abbott)
Genentech, Inc.

Completed

Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib

Advanced Renal Cell Carcinoma

United States, Canada
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

First Time Use of SD-809 in Huntington Disease (First-HD)

Chorea

United States, Australia, Canada
Peking Union Medical College Hospital

Not yet recruiting

Efficacy of Sr-89 for Differentiated Thyroid Cancer With Bone Metastases

Bone Metastases | Thyroid Neoplasm Follicular

China
Auspex Pharmaceuticals, Inc.

Completed

Alternatives for Reducing Chorea in Huntington Disease (ARC-HD)

Chorea Associated With Huntington Disease

United States, Australia, Canada

Search clinical trials for: 8H9

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uzbekistan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations